Literature DB >> 19435866

Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).

Manal Mehibel1, Simendra Singh, Edwin C Chinje, Rachel L Cowen, Ian J Stratford.   

Abstract

Tumor-associated macrophages (TAMs) are found in many solid tumors and have often been shown to accumulate in the hypoxic regions surrounding areas of necrosis. TAMs are the major site of expression of nitric oxide synthase (NOS), a heme-containing homodimeric enzyme consisting of oxygenase and reductase domains. The latter has a high degree of sequence homology to cytochrome P450 reductase and a functional consequence of this is the ability of NOS, under hypoxic conditions, to activate the bioreductive drugs tirapazamine and RSU1069. Banoxantrone (AQ4N) is a bioreductive prodrug activated in hypoxia by an oxygen-dependent two-electron reductive process to yield the topoisomerase II inhibitor AQ4. A feature of this process is that the final product could potentially show bystander cell killing. Thus, in this study, we investigated the ability of inducible NOS (iNOS)-expressing TAMs to activate AQ4N and elicit toxicity in cocultured human tumor cells. Murine macrophages were induced to overexpress iNOS by treatment with a combination of cytokines, mixed with HT1080 and HCT116 human tumor cells, and the toxicity of AQ4N was determined under aerobic or hypoxic conditions. The aerobic toxicity of AQ4N toward tumor cells was not affected through coculturing with macrophages. However, under hypoxic conditions, the induction of iNOS activity in the macrophages was associated with an increase in AQ4N metabolism and a substantial increase in tumor cell toxicity, which was dependent on the proportion of macrophages in the culture. This study is the first demonstration of TAM-mediated prodrug activation to result in bystander killing of human tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435866     DOI: 10.1158/1535-7163.MCT-08-0927

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  12 in total

Review 1.  Nitric oxide and cancer therapy: the emperor has NO clothes.

Authors:  Jason R Hickok; Douglas D Thomas
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

2.  In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling.

Authors:  Karen A Nolan; Mark S Dunstan; Mary C Caraher; Katherine A Scott; David Leys; Ian J Stratford
Journal:  Mol Cancer Ther       Date:  2011-11-16       Impact factor: 6.261

3.  Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Authors:  Eugene Manley; David J Waxman
Journal:  J Pharmacol Exp Ther       Date:  2012-11-28       Impact factor: 4.030

4.  Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.

Authors:  Manal Mehibel; Simendra Singh; Rachel L Cowen; Kaye J Williams; Ian J Stratford
Journal:  Oncol Rep       Date:  2016-01-13       Impact factor: 3.906

5.  Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma.

Authors:  Da Zhang; Aixian Zheng; Juan Li; Ming Wu; Lingjie Wu; Zuwu Wei; Naishun Liao; Xiaolong Zhang; Zhixiong Cai; Huanghao Yang; Gang Liu; Xiaolong Liu; Jingfeng Liu
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

6.  KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation.

Authors:  Paolo Lazzari; Marco Spiga; Monica Sani; Matteo Zanda; Ian N Fleming
Journal:  Hypoxia (Auckl)       Date:  2017-05-23

7.  M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway.

Authors:  Juan Lv; Chao Liu; Fu-Kun Chen; Zhi-Ping Feng; Li Jia; Peng-Jie Liu; Zhi-Xian Yang; Fei Hou; Zhi-Yong Deng
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

8.  Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions-in vitro study.

Authors:  Sravan Kumar Patel; Yang Zhang; John A Pollock; Jelena M Janjic
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

Review 9.  Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.

Authors:  Roger M Phillips
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333

10.  The NF-κB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription.

Authors:  Priscilla S Simon; Sarah K Sharman; Chunwan Lu; Dafeng Yang; Amy V Paschall; Sidhartha S Tulachan; Kebin Liu
Journal:  BMC Cancer       Date:  2015-10-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.